CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241210306 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Jun Se Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Bio and Medical Technology Development Program of the National Research Foundation (NRF).
Abstract (Originalsprache)
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy owing to relapse caused by resistance to chemotherapy. We previously reported that cluster of differentiation 109 (CD109) expression is positively correlated with poor prognosis and chemoresistance in patients with EOC. To further explore the role of CD109 in EOC, we explored the signaling mechanism of CD109-induced drug resistance. We found that CD109 expression was upregulated in doxorubicin-resistant EOC cells (A2780-R) compared with that in their parental cells. In EOC cells (A2780 and A2780-R), the expression level of CD109 was positively correlated with the expression level of ATP-binding cassette (ABC) transporters, such as ABCB1 and ABCG2, and paclitaxel (PTX) resistance. Using a xenograft mouse model, it was confirmed that PTX administration in xenografts of CD109-silenced A2780-R cells significantly attenuated in vivo tumor growth. The treatment of CD109-overexpressed A2780 cells with cryptotanshinone (CPT), a signal transducer and activator of transcription 3 (STAT3) inhibitor, inhibited the CD109 overexpression-induced activation of STAT3 and neurogenic locus notch homolog protein 1 (NOTCH1), suggesting a STAT3-NOTCH1 signaling axis. The combined treatment of CD109-overexpressed A2780 cells with CPT and N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT), a NOTCH inhibitor, markedly abrogated PTX resistance. These results suggest that CD109 plays a key role in the acquisition of drug resistance by activating the STAT3-NOTCH1 signaling axis in patients with EOC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea.
- Hicelltech Inc., Yangsan 50612, Republic of Korea.
- Department of Pathology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea.
- Department of Obstetrics and Gynecology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea.
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), Daegu 41061, Republic of Korea.
ORCID-Profile: Jun Se Kim, Seo Yul Lee, Dong-Soo Suh, Jae Ho Kim
Förderung
- National Research Foundation of Korea
- Bio and Medical Technology Development Program of the National Research Foundation (NRF)
Zitieren
APA
Kim, J. S., Shin, M. J., Lee, S. Y., Kim, D. K., Choi, K. U., Suh, D. S., Kim, D., & Kim, J. H. (2023). CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241210306
Vancouver
Kim JS, Shin MJ, Lee SY, Kim DK, Choi KU, Suh DS, et al. CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241210306
BibTeX
@article{Kim2023,
author = {Kim, Jun Se and Shin, Min Joo and Lee, Seo Yul and Kim, Dae Kyoung and Choi, Kyung-Un and Suh, Dong-Soo and Kim, Dayea and Kim, Jae Ho},
title = {CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241210306}
}
EUVIMED